FINWIRES · TerminalLIVE
FINWIRES

据报道,菲律宾寻求美国延长对购买俄罗斯能源的豁免期限。

-- 据多家媒体周二报道,菲律宾能源部长莎伦·加林表示,菲律宾已向美国提出申请,希望延长其从俄罗斯购买石油和石油产品的豁免期限。 加林在周二的新闻发布会上表示,尽管政府希望获得豁免延期,但如果美国拒绝这一请求,政府也在制定其他采购方案。 路透社援引加林的话报道称,菲律宾政府正在探索从南美(包括哥伦比亚和阿根廷)以及加拿大和美国等生产商采购的可能性,以实现能源来源多元化。 报道称,从俄罗斯进口石油产品为菲律宾提供了更多多元化选择。 菲律宾驻美国大使何塞·曼努埃尔·罗穆亚尔德斯对获得美国批准延长豁免期限充满信心,他表示其他国家也曾寻求过类似的延期,他们只需要向美国国务院和财政部提供有关数量和期限的详细信息即可。已分别联系 Garin 和菲律宾能源部征求意见。

Related Articles

Asia

Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%

Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.

$KOSDAQ:440110
Asia

ASX Biggest Losers

Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07

$^AXJO$ASX:COH$ASX:EVT$ASX:NXG$ASX:ORG$ASX:PDN$ASX:RHC$ASX:SX2$ASX:TLX$ASX:TUA$ASX:WTC
Asia

Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal

Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.

$BOM:524715$NSE:SUNPHARMA